MedCap’s Business Area Specialty Pharma Completes the Acquisition of XGX Pharma

Regulatory

MedCap’s wholly owned subsidiary, Unimedic Pharma AB, has today completed the previously announced acquisition of 100% of the shares in XGX Pharma ApS (“XGX”) in Denmark.

The acquisition was announced on June 25, 2025, and has now received the necessary regulatory approval (Foreign Direct Investment) in Denmark.

The information was submitted for publication, through the agency of the contact person, on 21-07-2025 12:00 CEST.

For more information, contact:

Anders Dahlberg, CEO, Mobile +46 704 26 92 62,  e-mail anders.dahlberg@medcap.se

About MedCap

MedCap builds successful life sciences companies to improve people's lives. MedCap unites the strengths of a larger the company with the smaller companies' entrepreneurial power, agility, and business acumen. MedCap is publicly listed on NASDAQ Stockholm OMX, with the symbol MCAP. More information is available on the company web site www.medcap.se. 

Attachments
MedCap completes the acquisition of Xgx Pharma 20250721